The effect of fluoride therapy on blood chemistry parameters in osteoporotic females.
To determine the potential adverse effects, if any, of long-term fluoride ingestion in humans, samples were collected from 25 adult females taking daily doses of fluoride (mean, 23 mg elemental F) for the treatment of osteoporosis and from 38 osteoporotic female controls. Patients in the fluoride group had been receiving therapy for approximately 18 months with a mean duration of 4.2 years and had serum fluoride values of at least 10 mumol/l. Laboratory analyses for fluoride were conducted on plasma, urine and drinking water samples collected from each panelist. Blood was also collected for blood chemistry analyses and plasma lymphocytes were examined for the frequency of sister chromatid exchange (SCE). Plasma and urine fluoride levels were significantly different between the two groups, while water fluoride was not. The SCE frequency, a measurement of potential genotoxicity, did not differ between the two groups. Of the blood chemistry parameters measured, albumin, alkaline phosphatase, sodium, chloride, the albumin/globulin (A/G) ratio, indirect bilirubin, lactate dehydrogenase (LDH), and gamma-glutamyl transferase (GGT) were found to be significantly different between the two groups (P < or = 0.05). However, none of the mean group values were outside stated normal ranges for any of these parameters. We conclude that the risk of developing adverse systemic effects from the ingestion of fluoride, at dosages and for a duration comparable with that of our panel, is minimal.
Oral Health Research Institute, Indiana University School of Dentistry, Indianapolis 46202-2876.
R
R
Jackson
S
S
Kelly
T
T
Noblitt
W
W
Zhang
A
A
Dunipace
Y
Y
Li
G
G
Stookey
B
B
Katz
E
E
Brizendine
S
S
Farley
D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D000704:Analysis of Variance; D001663:Bilirubin / Q000097:blood; D001774:Blood Chemical Analysis; D001842:Bone and Bones / Q000201:enzymology; D002119:Calcium Carbonate / Q000627:therapeutic use; D002712:Chlorides / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D005459:Fluorides / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008099:Liver / Q000201:enzymology; D008214:Lymphocytes / Q000187:drug effects; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D012709:Serum Albumin / Q000378:metabolism; D012712:Serum Globulins / Q000378:metabolism; D012854:Sister Chromatid Exchange / Q000187:drug effects / Q000235:genetics; D012964:Sodium / Q000097:blood; D014867:Water / Q000737:chemistry; D005723:gamma-Glutamyltransferase / Q000097:blood
D002712:Chlorides; D012709:Serum Albumin; D012712:Serum Globulins; D014867:Water; D012964:Sodium; D007770:L-Lactate Dehydrogenase; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase; D002119:Calcium Carbonate; D005459:Fluorides; D001663:Bilirubin